Clenbuterol, bụ β2-adrenergic agonist (β2-adrenergic agonist), nke yiri ephedrine (Ephedrine), a na-ejikarị ya agwọ ọrịa akpa ume na-adịghị ala ala (COPD). A na-ejikwa ya dị ka bronchodilator iji belata nnukwu nsogbu nke ụkwara ume ọkụ. Na mbido afọ 1980, ụlọ ọrụ America bụ Cyanamid chọpụtara na mberede na o nwere mmetụta doro anya nke ịkwalite uto, imeziwanye ọnụego anụ dị nro na ibelata abụba, yabụ ejiri ya dị ka clenbuterol na ịzụ anụmanụ. Agbanyeghị, n'ihi mmetụta ọjọọ ya, European Community machibidoro iji clenbuterol dị ka ihe mgbakwunye nri kemgbe Jenụwarị 1, 1988. FDA machibidoro ya na 1991. Na 1997, Ministry of Agriculture of the People's Republic of China machibidoro iji homonụ beta-adrenergic eme ihe na mmepụta nri na ịzụ anụmanụ, Clenbuterol hydrochloride nọkwa n'ọkwa mbụ.
Agbanyeghị, a hụla na Clenbuterol racemic na-ebelata ihe ize ndụ nke ọrịa Parkinson. Iji gosi na isomers (ma ọ bụ ha abụọ) na-emepụta mmetụta a, ọ dị mkpa ka a mụọ Clenbuterol enantiomer dị ọcha iche iche.
N'isiokwu e bipụtara n'oge na-adịbeghị anya, otu nnyocha nke Elisabeth Egholm Jacobsen nke Ngalaba Kemịstrị, Mahadum Sayensị na Teknụzụ nke Norway, na Dr. Zhu Wei nke Shangke Bio, mere ka mmepụta nke ketoreductase KRED na cofactor nicotinamide adenine dinucleoside phosphate (NADPH) ka mma. (R)-1-(4-Amino-3,5-dichlorophenyl)-2-bromoethan-1-ol, ee > 93%; na otu sistemụ ,6-Dichloro-4-(1-hydroxyethyl)phenyl)acetamide, nke >98%, mepụtara (S)-N-(2). Ketoreductase ES-KRED-228 ejiri mee nnyocha a sitere na Shangke Biopharmaceutical (Shanghai) Co., Ltd. Nsonaazụ nyocha ahụ bụ "Chemoenzymatic Synthesis of Synthons as Precursors for Enantiopure Clenbuterol and Other -2-Agonists" ka ebipụtara na "Catalysts" na Nọvemba 4, 2018.
Oge ozi: Ọgọst-26-2022